University Hospital Bonn, Center for Integrated Oncology (CIO) , Bonn , Germany.
Expert Opin Biol Ther. 2014 Jul;14(7):905-16. doi: 10.1517/14712598.2014.900537. Epub 2014 Mar 28.
Cytokine-induced killer (CIK) cells are mainly CD3(+)CD56(+) NKT cells exhibiting non-MHC-restricted cytotoxicity against a broad range of tumors. Much research is going on to improve CIK cell effectivity and to evaluate the clinical benefit of different combinations with conventional therapies.
This review provides an update on in vitro/in vivo studies and clinical trials applying CIK cells for the treatment of solid tumors. This comprises attempts using additional cytokines, genetic engineering and combinations with different conventional and modern therapies.
Since our last review, much effort has been made to improve CIK cell cytotoxicity and clinical effectivity. Targeted CIK cell therapy and combinations of CIK cells with antiangiogenic drugs or oncolytic viruses are examples of recent outstanding achievements in the field of adoptive CIK cell therapy. The clinical application of CIK cells in combination with conventional therapies, especially, obtained promising results. However, the best combination and the optimal therapy schedule have yet to be defined.
细胞因子诱导的杀伤（CIK）细胞主要是 CD3(+)CD56(+)NKT 细胞，对广泛的肿瘤具有非 MHC 限制的细胞毒性。目前正在进行大量研究以提高 CIK 细胞的有效性，并评估不同组合与常规疗法的临床获益。
本综述提供了关于应用 CIK 细胞治疗实体瘤的体外/体内研究和临床试验的最新信息。这包括使用额外细胞因子、基因工程以及与不同常规和现代疗法联合应用的尝试。
自我们上次综述以来，人们已经做出了很大的努力来提高 CIK 细胞的细胞毒性和临床有效性。靶向 CIK 细胞治疗以及 CIK 细胞与抗血管生成药物或溶瘤病毒的联合应用是过继性 CIK 细胞治疗领域的最新杰出成就的例子。CIK 细胞与常规疗法联合应用的临床应用取得了有希望的结果。然而，最佳组合和最佳治疗方案仍有待确定。
